EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update
Methodological detailsEULAR task force, systematic literature review and consensus, predefined voting process, level of evidence and strength of recommendation assigned, level of agreement
- EULAR task force, systematic literature review and consensus
- Predefined voting process
- Level of evidence and strength of recommendation assigned
- Level of agreement
Recommendations
As issued by the authors
Synthetic disease-modifying antirheumatic drugs (DMARDs) compatible with pregnancy include antimalarials, AZA, colchicine, cyclosporine, SSZ and tacrolimus.
Nonsteroidal anti-inflammatory drugs (NSAIDs) and GCs: a more restrictive approach to their use during pregnancy is recommended.
Based on an individualised risk-benefit assessment, all tumour necrosis factor inhibitor (TNFi) bDMARDs can be used throughout pregnancy, and non-TNFi bDMARDs may be used if needed.
Lactation: compatible drugs include antimalarials, AZA, colchicine, cyclosporine, GCs, intravenous immunoglobulin (IVIG), NSAIDs, SSZ and tacrolimus.
All bDMARDs are considered compatible with breastfeeding.
Men: compatible options include antimalarials, AZA, colchicine, cyclosporine, IVIG, LEF, MTX, mycophenolate, NSAIDs, GCs, sildenafil, SSZ, tacrolimus and bDMARDs.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →